keyword
MENU ▼
Read by QxMD icon Read
search

Gastroesophageal junction cancer

keyword
https://www.readbyqxmd.com/read/29430123/testicular-metastasis-from-recurrent-gastroesophageal-junction-adenocarcinoma-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-findings
#1
Ishan Garg, Maria Jose Baladron Zanetti, Ayse Tuba Kendi
Testicular metastasis from gastroesophageal junction (GEJ) adenocarcinoma is a very rare condition. A 57-year-old male with a history of neoadjuvant chemotherapy and surgery for HER-2-positive GEJ adenocarcinoma underwent a follow-up 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). It revealed multiple metastases including bilateral testicular and L4 laminar metastasis. The patient received multiple chemotherapies, but follow-up PET/CT showed interval progression of disease...
January 2018: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/29416812/prognostic-value-of-resected-lymph-nodes-numbers-for-siewert-ii-gastroesophageal-junction-cancer
#2
Sanchuan Lai, Tingting Su, Xingkang He, Zhenghua Lin, Shujie Chen
We aim to evaluate whether resected lymph nodes (RLNs) numbers have prognostic value in patients with gastroesophageal junction cancers (GEJ, Siewert type II). Patients with gastroesophageal junction cancers were identified from the Surveillance Epidemiology and End Results (SEER) registry between 1988 to 2013. Multivariate Cox regression analyses and Kaplan-Meier method were performed to analyze risk factors for overall survival (OS) and cause-specific survival(CSS). A total of 8396 patients who underwent surgeries and had reginal lymph nodes examined were identified...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29397460/ramucirumab-for-the-treatment-of-patients-with-gastric-or-gastroesophageal-junction-cancer-in-community-oncology-practices
#3
A Scott Paulson, Lisa M Hess, Astra M Liepa, Zhanglin Lin Cui, Kathleen M Aguilar, Jamyia Clark, William Schelman
BACKGROUND: Limited real-world research has investigated ramucirumab for the treatment of patients with gastric or gastroesophageal junction (GEJ) cancer. This study was designed to describe ramucirumab monotherapy or combination therapy use in a community oncology practice setting. METHODS: This was a retrospective observational cohort study to describe the treatment of adult patients with gastric or GEJ cancer who initiated ramucirumab treatment between 4/21/14 and 6/30/16 within the US Oncology Network...
February 3, 2018: Gastric Cancer
https://www.readbyqxmd.com/read/29370182/correlation-of-pathological-complete-response-with-survival-after-neoadjuvant-chemotherapy-in-gastric-or-gastroesophageal-junction-cancer-treated-with-radical-surgery-a-meta-analysis
#4
Ziyu Li, Fei Shan, Yinkui Wang, Yan Zhang, Lianhai Zhang, Shuangxi Li, Yongning Jia, Kan Xue, Rulin Miao, Zhemin Li, Jiafu Ji
BACKGROUND: Neoadjuvant chemotherapy before radical gastrectomy is preferred for locally advanced gastric cancer. To avoid the problematic use of pTNM for patients after neoadjuvant chemotherapy, the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) gastric cancer TNM staging system (8th edition) added ypTNM for the first time. But patients achieving pathological complete response were not covered by the new ypTNM staging system. To investigate whether pathological complete response is associated with better outcome in gastric cancer, as was reported in rectal, breast and bladder cancer...
2018: PloS One
https://www.readbyqxmd.com/read/29350579/evaluation-of-respiratory-motion-corrected-cone-beam-ct-at-end-expiration-in-abdominal-radiotherapy-sites-a-prospective-study
#5
Russell E Kincaid, Agung E Hertanto, Yu-Chi Hu, Abraham J Wu, Karyn A Goodman, Hai D Pham, Ellen D Yorke, Qinghui Zhang, Qing Chen, Gig S Mageras
BACKGROUND: Cone beam computed tomography (CBCT) for radiotherapy image guidance suffers from respiratory motion artifacts. This limits soft tissue visualization and localization accuracy, particularly in abdominal sites. We report on a prospective study of respiratory motion-corrected (RMC)-CBCT to evaluate its efficacy in localizing abdominal organs and improving soft tissue visibility at end expiration. MATERIAL AND METHODS: In an IRB approved study, 11 patients with gastroesophageal junction (GEJ) cancer and five with pancreatic cancer underwent a respiration-correlated CT (4DCT), a respiration-gated CBCT (G-CBCT) near end expiration and a one-minute free-breathing CBCT scan on a single treatment day...
January 19, 2018: Acta Oncologica
https://www.readbyqxmd.com/read/29340092/first-line-dose-dense-chemotherapy-with-docetaxel-cisplatin-folinic-acid-and-5-fluorouracil-dcf-plus-panitumumab-in-patients-with-locally-advanced-or-metastatic-cancer-of-the-stomach-or-gastroesophageal-junction-final-results-and-biomarker-analysis-from-an
#6
Gianluca Tomasello, Nicola Valeri, Michele Ghidini, Elizabeth C Smyth, Wanda Liguigli, Laura Toppo, Rodolfo Mattioli, Alessandra Curti, Jens C Hahne, Federica M Negri, Stefano Panni, Margherita Ratti, Silvia Lazzarelli, Fabiana Gerevini, Chiara Colombi, Andrea Panni, Massimo Rovatti, Leonardo Treccani, Mario Martinotti, Rodolfo Passalacqua
Background: Survival for patients with advanced gastroesophageal cancer (AGC) using standard treatment regimens is poor. EGFR overexpression is common in AGC and associated with poor prognosis. We hypothesized that increasing the dose intensity of chemotherapy and adding panitumumab could improve efficacy. Methods: HER2 negative, PS 0-1 patients, received up to 4 cycles of panitumumab 6 mg/kg d 1, docetaxel 60 mg/m2 d 1, cisplatin 50 mg/m2 d 1, l-folinic acid 100 mg/m2 d 1-2, followed by 5-FU 400 mg/m2 bolus d 1-2, and then 600 mg/m2 as a 22 h c...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29333068/nab-paclitaxel-as-second-line-treatment-in-advanced-gastric-cancer-a-multicenter-phase-ii-study-of-the-hellenic-oncology-research-group
#7
Panagiotis Katsaounis, Athanasios Kotsakis, Nikolaos Kentepozidis, Aris Polyzos, Marios Bakogeorgos, Filippos Koinis, Lambros Vamvakas, Nikolaos Vardakis, Kostas Kalbakis, Ioannis Boukovinas, Ioannis I Varthalitis, Efthimios Prinarakis, Vassilis Georgoulias, John Souglakos
Background: This study evaluated the safety and efficacy of nab-paclitaxel as second-line treatment in patients with advanced gastric adenocarcinoma. Methods: Thirty-nine pretreated patients [33 with taxane-based regimens (docetaxel, cisplatin, and fluorouracil)] and 6 with combination of fluoropyrimidines plus cisplatin with locally advanced inoperable and metastatic gastric and gastroesophageal junction adenocarcinoma were treated with weekly nab-paclitaxel (150 mg/m2 d1, d8, d15 in cycles of 28 days)...
January 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29318751/subgroup-analysis-of-east-asian-patients-in-regard-a-phase-iii-trial-of-ramucirumab-and-best-supportive-care-for-advanced-gastric-cancer
#8
Hyun Cheol Chung, Victor C Kok, Rebecca Cheng, Yanzhi Hsu, Mauro Orlando, Charles Fuchs, Jae Yong Cho
AIM: We describe a subgroup analysis assessing the efficacy and safety of ramucirumab monotherapy in East Asian (EA) patients from the REGARD trial. METHODS: Patients with advanced gastric or gastroesophageal junction adenocarcinoma with progressive disease were randomized 2:1 to receive ramucirumab (8 mg/kg) plus best supportive care (BSC) or placebo plus BSC every 2 weeks. Post hoc subset analyses were performed on the EA and non-EA intention-to-treat populations...
January 10, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29297698/a-clinical-trial-protocol-paper-discussing-the-brighter-study
#9
Mohamad Bassam Sonbol, Tanios Bekaii-Saab
Napabucasin is a novel oral first-in-class cancer stemness inhibitor. Preclinical and early phase clinical trials showed promising antitumor efficacy signals for napabucasin in a variety of malignancies. In this article, we describe the design and rationale for the now completed BRIGHTER trial, a multicenter, randomized, placebo-controlled, Phase III study designed to determine the efficacy and safety of combining napabucasin with paclitaxel in previously treated patients with advanced gastric and gastroesophageal junction adenocarcinoma (NCT02178956)...
January 3, 2018: Future Oncology
https://www.readbyqxmd.com/read/29290655/endoscopic-ultrasound-staging-for-early-esophageal-cancer-are-we-denying-patients-neoadjuvant-chemo-radiation
#10
Carrie Luu, Marisa Amaral, Jason Klapman, Cynthia Harris, Khaldoun Almhanna, Sarah Hoffe, Jessica Frakes, Jose M Pimiento, Jacques P Fontaine
AIM: To evaluate the accuracy of endoscopic ultrasound (EUS) in early esophageal cancer (EC) performed in a high-volume tertiary cancer center. METHODS: A retrospective review of patients undergoing esophagectomy was performed and patients with cT1N0 and cT2N0 esophageal cancer by EUS were evaluated. Patient demographics, tumor characteristics, and treatment were reviewed. EUS staging was compared to surgical pathology to determine accuracy of EUS. Descriptive statistics was used to describe the cohort...
December 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29285491/detection-of-met-amplification-in-gastroesophageal-tumor-specimens-using-iqfish
#11
Jan Trøst Jørgensen, Karsten Bork Nielsen, Jens Mollerup, Anna Jepsen, Ning Go
Background: The gene mesenchymal epithelial transition factor (MET) is a proto-oncogene that encodes a transmembrane receptor with intrinsic tyrosine kinase activity known as Met or cMet. MET is found to be amplified in several human cancers including gastroesophageal cancer. Methods: Here we report the MET amplification prevalence data from 159 consecutive tumor specimens from patients with gastric (G), gastroesophageal junction (GEJ) and esophageal (E) adenocarcinoma, using a novel fluorescence in situ hybridization (FISH) assay, MET/CEN-7 IQFISH Probe Mix [an investigational use only (IUO) assay]...
December 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29282511/locoregional-tumor-extension-and-preoperative-smoking-are-significant-risk-factors-for-early-recurrence-after-esophagectomy-for-cancer
#12
Styliani Mantziari, Pierre Allemann, Michael Winiker, Nicolas Demartines, Markus Schäfer
BACKGROUND: Tumor recurrence during the first year after oncological esophagectomy has been reported in up to 17-66% of patients. However, little is known as to the risk factors potentially associated with this adverse outcome. The aim of this retrospective observational study was to identify clinically relevant parameters associated with early recurrence. METHODS: All patients with squamous cell cancer or adenocarcinoma of the esophagus or gastroesophageal junction, operated with curative intent in our center from 2000 to 2014, were screened for this study...
December 28, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/29282088/the-renaissance-aio-flot5-trial-effect-of-chemotherapy-alone-vs-chemotherapy-followed-by-surgical-resection-on-survival-and-quality-of-life-in-patients-with-limited-metastatic-adenocarcinoma-of-the-stomach-or-esophagogastric-junction-a-phase-iii-trial-of-the
#13
Salah-Eddin Al-Batran, Thorsten O Goetze, Daniel W Mueller, Arndt Vogel, Michael Winkler, Sylvie Lorenzen, Alexander Novotny, Claudia Pauligk, Nils Homann, Thomas Jungbluth, Christoph Reissfelder, Karel Caca, Steffen Retter, Eva Horndasch, Julia Gumpp, Claus Bolling, Karl-Hermann Fuchs, Wolfgang Blau, Winfried Padberg, Michael Pohl, Andreas Wunsch, Patrick Michl, Frank Mannes, Matthias Schwarzbach, Harald Schmalenberg, Michael Hohaus, Christian Scholz, Christoph Benckert, Jorge Riera Knorrenschild, Veit Kanngießer, Thomas Zander, Hakan Alakus, Ralf-Dieter Hofheinz, Claus Roedel, Manish A Shah, Mitsuru Sasako, Dietmar Lorenz, Jakob Izbicki, Wolf O Bechstein, Hauke Lang, Stefan P Moenig
BACKGROUND: Historical data indicate that surgical resection may benefit select patients with metastatic gastric and gastroesophageal junction cancer. However, randomized clinical trials are lacking. The current RENAISSANCE trial addresses the potential benefits of surgical intervention in gastric and gastroesophageal junction cancer with limited metastases. METHODS: This is a prospective, multicenter, randomized, investigator-initiated phase III trial. Previously untreated patients with limited metastatic stage (retroperitoneal lymph node metastases only or a maximum of one incurable organ site that is potentially resectable or locally controllable with or without retroperitoneal lymph nodes) receive 4 cycles of FLOT chemotherapy alone or with trastuzumab if Her2+...
December 28, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29280460/preoperative-chemoradiation-therapy-does-not-increase-risk-of-anastomotic-leak-in-patients-with-gastric-cancer
#14
Naruhiko Ikoma, Prajnan Das, Mariela Blum, Jeannelyn S Estrella, Catherine E Devine, Xuemei Wang, Keith Fournier, Paul Mansfield, Bruce D Minsky, Jaffer Ajani, Brian D Badgwell
INTRODUCTION: We sought to determine whether preoperative chemoradiation therapy or chemotherapy increases the risk of anastomotic leak after gastrectomy in gastric cancer patients without gastroesophageal junction involvement. METHODS: We reviewed data from a prospectively maintained database of patients who underwent gastrectomy at our institution between 2001 and 2016. The incidence of anastomotic leak and symptomatic intra-abdominal fluid collection was determined and tested for associations with the type of preoperative therapy...
November 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29278841/patient-education-level-affects-treatment-allocation-and-prognosis-in-esophageal-and-gastroesophageal-junctional-cancer-in-sweden
#15
Gustav Linder, Fredrik Sandin, Jan Johansson, Mats Lindblad, Lars Lundell, Jakob Hedberg
BACKGROUND: Low socioeconomic status and poor education elevate the risk of developing esophageal- and junctional cancer. High education level also increases survival after curative surgery. The present study aimed to investigate associations, if any, between patient education-level and treatment allocation after diagnosis of esophageal- and junctional cancer and its subsequent impact on survival. METHODS: A nation-wide cohort study was undertaken. Data from a Swedish national quality register for esophageal cancer (NREV) was linked to the National Cancer Register, National Patient Register, Prescribed Drug Register, Cause of Death Register and educational data from Statistics Sweden...
December 23, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/29234525/invasive-candida-infection-after-upper-gastrointestinal-tract-surgery-for-gastric-cancer
#16
Evgeni Brotfain, Gilbert Sebbag, Michael Friger, Boris Kirshtein, Abraham Borer, Leonid Koyfman, Dmitry Frank, Yoav Bichovsky, Jochanan G Peiser, Moti Klein
Upper gastrointestinal tract (GIT) surgical procedures are more likely to cause nosocomial Candida peritonitis than lower GIT procedures and they thus constitute an independent risk factor for mortality. Because of the severity of postsurgical fungal infections complications, intensivists and surgeons need to be extremely aware of their clinical importance in critically ill postsurgical intensive care unit (ICU) patients. We analyzed the clinical and microbiological data of 149 oncologic patients who were hospitalized in the ICU at Soroka Medical Center between January 2010 and January 2015 after undergoing upper GIT surgery for gastric cancer...
2017: International Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29228632/survival-benefit-of-anti-angiogenic-agents-in-patients-with-previously-treated-advanced-gastric-or-gastroesophageal-junction-cancer-a-meta-analysis
#17
Jung Han Kim, Hyeong Su Kim, Bum Jun Kim, Hyun Joo Jang
There is a debate as to whether anti-angiogenic molecular agents can produce survival benefits in patients with previously treated advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC). We performed this meta-analysis of randomized trials to evaluate the survival outcomes of an anti-angiogenic agent versus placebo in the salvage treatment of advanced GC or GEJC. Electronic databases were searched for eligible studies. From the four studies, 910 patients with previously treated advanced GC or GEJC were included in the meta-analysis...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29215372/efficacy-and-safety-of-apatinib-as-second-line-therapy-for-advanced-gastric-cancer-a-single-center-observational-study
#18
Yong Zhang, Miaomiao Gou, Chun Han, Juan Li, Lijie Wang, Qian Qiao, Yi Hu, Li Bai, Zhefeng Liu
Apatinib has been proven to be effective and safe among patients in the third-line treatment of advanced gastric cancer in phase II and III trials. We aimed to evaluate its efficacy and safety in second-line practice, and to explore the factors associated with efficacy. Between April 2015 and May 2017, a total of 23 patients with advanced gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction were enrolled and followed up retrospectively after failing the first line of systemic therapy. The median progression-free survival was 4...
December 5, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29182797/palliative-chemotherapy-and-targeted-therapies-for-esophageal-and-gastroesophageal-junction-cancer
#19
REVIEW
Vincent T Janmaat, Ewout W Steyerberg, Ate van der Gaast, Ron Hj Mathijssen, Marco J Bruno, Maikel P Peppelenbosch, Ernst J Kuipers, Manon Cw Spaander
BACKGROUND: Almost half of people with esophageal or gastroesophageal junction cancer have metastatic disease at the time of diagnosis. Chemotherapy and targeted therapies are increasingly used with a palliative intent to control tumor growth, improve quality of life, and prolong survival. To date, and with the exception of ramucirumab, evidence for the efficacy of palliative treatments for esophageal and gastroesophageal cancer is lacking. OBJECTIVES: To assess the effects of cytostatic or targeted therapy for treating esophageal or gastroesophageal junction cancer with palliative intent...
November 28, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29154240/polish-consensus-on-treatment-of-gastric-cancer-update-2017
#20
Jan Kulig, Grzegorz Wallner, Michał Drews, Mariusz Frączek, Arkadiusz Jeziorski, Wojciech Kielan, Piotr Kołodziejczyk, Anna Nasierowska-Guttmejer, Teresa Starzyńska, Krzysztof Zinkiewicz, Marek Wojtukiewicz, W Tomasz Skoczylas, Piotr Richter, Marek Krawczyk
The "Polish Research on Gastric Cancer" project has been continued since 1986. The main aim of this project, which is a multicenter and interdisciplinary research, is enhancing the treatment results of gastric cancer patients by developing and promoting the use of optimal methods for diagnosis and treatment, both surgical as well as combined. One of the more important achievements of the project is the development and publication of a document named "Polish Consensus on Treatment of Patients with Gastric Cancer", whose first version was published in 1998...
October 31, 2017: Polski Przeglad Chirurgiczny
keyword
keyword
50345
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"